HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma

被引：0
|
作者：
Yan Jia
Jianing Zhao
Chunqing Wang
Jing Meng
Liqing Zhao
Hongwei Yang
Xiaoqing Zhao
机构：
[1] Tianjin Hospital,Department of Laboratory Medicine
[2] The Fourth Hospital of Hebei Medical University,Department of Pathology
[3] The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,Department of Clinical Laboratory Medicine
[4] Shandong Medicine and Health Key Laboratory of Laboratory Medicine,Department of Clinical Laboratory
[5] The Second Hospital,Department of Pediatrics
[6] Cheeloo College of Medicine,undefined
[7] Shandong University,undefined
[8] Zaozhuang Municipal Hospital,undefined
来源：
Journal of Translational Medicine | / 22卷
关键词：
Hepatocellular carcinoma; T cell dysfunction; HBV DNA polymerase; PD-L1; PARP1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Observational Study of PD-L1, TGF-β and Immune Cell Infiltrates in Hepatocellular Carcinoma
    Ihling, Christian
    Naughton, Bartholomew
    Zhang, Yue
    Rolfe, P. Alexander
    Frick-Krieger, Eveline
    Terracciano, Luigi M.
    Dussault, Isabelle
    FRONTIERS IN MEDICINE, 2019, 6
  • [32] The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma
    Xu, Hao
    Liang, Xiao-Lu
    Liu, Xiao-Guang
    Chen, Nian-Ping
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (03) : 1132 - +
  • [33] Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
    Wang, Jiting
    Li, Jun
    Tang, Guiju
    Tian, Yuan
    Su, Song
    Li, Yaling
    ONCOLOGY LETTERS, 2021, 21 (04) : 1 - 8
  • [34] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] PD-L1 Expression is an Unfavorable Prognostic Factor in Hepatocellular Carcinoma
    Baek, M.
    Jung, H.
    Ahn, T.
    Park, S.
    Bae, S.
    Jung, D.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S111 - S111
  • [36] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [37] Comparing the performance of three PD-L1 antibodies for PD-L1 expression in renal cell carcinoma
    Park, S.
    Wi, Y. C.
    Shin, S.
    Jang, K.
    VIRCHOWS ARCHIV, 2019, 475 : S181 - S182
  • [38] Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma
    Huang, Chun-yu
    Wang, Ying
    Luo, Guang-yu
    Han, Feng
    Li, Yong-qiang
    Zhou, Zhong-guo
    Xu, Guo-liang
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (09) : 323 - 333
  • [39] Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells
    Song, Shasha
    Yuan, Pingfan
    Wu, Huaxun
    Chen, Jingyu
    Fu, Jingjing
    Li, Peipei
    Lu, Jingtao
    Wei, Wei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 20 (01) : 117 - 123
  • [40] Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma
    Wei, Ting
    Li, Manjun
    Zhu, Zhigang
    Xiong, Huabao
    Shen, Han
    Zhang, Hui
    Du, Qinghua
    Li, Qingshan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (03) : 691 - 701
12345